SG Americas Securities LLC Acquires 14,423 Shares of AnaptysBio, Inc. $ANAB

SG Americas Securities LLC boosted its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 138.3% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,851 shares of the biotechnology company’s stock after buying an additional 14,423 shares during the quarter. SG Americas Securities LLC owned approximately 0.09% of AnaptysBio worth $1,378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ANAB. Granahan Investment Management LLC increased its position in AnaptysBio by 12.2% during the 3rd quarter. Granahan Investment Management LLC now owns 147,773 shares of the biotechnology company’s stock worth $4,525,000 after purchasing an additional 16,118 shares in the last quarter. Vanguard Group Inc. lifted its stake in AnaptysBio by 4.5% in the 4th quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock valued at $74,855,000 after purchasing an additional 67,048 shares during the last quarter. Sofinnova Investments Inc. lifted its stake in AnaptysBio by 13.1% in the 4th quarter. Sofinnova Investments Inc. now owns 287,690 shares of the biotechnology company’s stock valued at $13,947,000 after purchasing an additional 33,422 shares during the last quarter. BNP Paribas Financial Markets boosted its position in AnaptysBio by 56.0% in the fourth quarter. BNP Paribas Financial Markets now owns 164,823 shares of the biotechnology company’s stock valued at $7,991,000 after buying an additional 59,160 shares in the last quarter. Finally, 683 Capital Management LLC boosted its position in AnaptysBio by 18.5% in the fourth quarter. 683 Capital Management LLC now owns 648,093 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 101,093 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. HC Wainwright initiated coverage on shares of AnaptysBio in a report on Wednesday, June 10th. They set a “buy” rating and a $95.00 price target for the company. Weiss Ratings downgraded AnaptysBio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. UBS Group boosted their price objective on AnaptysBio from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Wednesday, May 13th. Barclays upped their target price on AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, May 13th. Finally, Leerink Partners set a $90.00 target price on AnaptysBio in a research report on Friday, May 15th. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, AnaptysBio currently has an average rating of “Moderate Buy” and a consensus price target of $81.82.

AnaptysBio Price Performance

ANAB opened at $63.42 on Friday. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The company’s 50 day moving average price is $59.81 and its two-hundred day moving average price is $56.29. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of -58.72 and a beta of 0.68.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by ($1.20). The firm had revenue of $25.56 million for the quarter, compared to analysts’ expectations of $18.86 million. As a group, equities research analysts predict that AnaptysBio, Inc. will post -1.35 EPS for the current year.

AnaptysBio declared that its Board of Directors has initiated a stock buyback program on Friday, March 27th that authorizes the company to buyback $100,000.00 billion in shares. This buyback authorization authorizes the biotechnology company to repurchase up to 5,352,316.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.